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Abstract
Background: In July 2000, the province of Ontario, Canada, initiated a universal influenza immunization program (UIIP) to
provide free seasonal influenza vaccines for the entire population. This is the first large-scale program of its kind worldwide.
The objective of this study was to conduct an economic appraisal of Ontario’s UIIP compared to a targeted influenza
immunization program (TIIP).
Methods and Findings: A cost-utility analysis using Ontario health administrative data was performed. The study was
informed by a companion ecological study comparing physician visits, emergency department visits, hospitalizations, and
deaths between 1997 and 2004 in Ontario and nine other Canadian provinces offering targeted immunization programs.
The relative change estimates from pre-2000 to post-2000 as observed in other provinces were applied to pre-UIIP Ontario
event rates to calculate the expected number of events had Ontario continued to offer targeted immunization. Main
outcome measures were quality-adjusted life years (QALYs), costs in 2006 Canadian dollars, and incremental cost-utility
ratios (incremental cost per QALY gained). Program and other costs were drawn from Ontario sources. Utility weights were
obtained from the literature. The incremental cost of the program per QALY gained was calculated from the health care
payer perspective. Ontario’s UIIP costs approximately twice as much as a targeted program but reduces influenza cases by
61% and mortality by 28%, saving an estimated 1,134 QALYs per season overall. Reducing influenza cases decreases health
care services cost by 52%. Most cost savings can be attributed to hospitalizations avoided. The incremental cost-
effectiveness ratio is Can$10,797/QALY gained. Results are most sensitive to immunization cost and number of deaths
averted.
Conclusions: Universal immunization against seasonal influenza was estimated to be an economically attractive
intervention.
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Worldwide, annual epidemics of influenza cause significant
morbidity and mortality and impose a considerable economic
burden on society in terms of health care costs and lost
productivity [1].
Seasonal prophylaxis with vaccines is the cornerstone of
influenza management. Influenza vaccines are generally safe and
effective. They reduce serologically confirmed influenza cases by
73% in healthy adults [2] and 58% in the elderly [3]. Influenza
vaccination in young children decreases the incidence of influenza
infection [4], acute otitis media [5,6], and daycare absenteeism
[7].
In most jurisdictions, seasonal prophylaxis with vaccines is
currently recommended for people at high risk of complications,
those capable of transmitting influenza to individuals at high risk
of complications, and those who provide essential community
services [8]. Nevertheless, vaccine coverage rates among high-risk
groups in Canada have been low in the past, substantially lower
than the target coverage rate (70%) set by a national consensus
conference on influenza in 1993 [9]. In response to these findings,
most provinces and territories in Canada offer free influenza
vaccinations for those 65 y or older, those with chronic medical
conditions, and health care workers (Targeted Influenza Immu-
nization Program, TIIP) [10]. The age-based recommendations in
the United States are more broad, including individuals 50 y or
older and children aged 6 mo to 18 y [11].
In 2000, the province of Ontario, Canada, initiated a universal
influenza immunization program (UIIP) [12] to provide free
influenza vaccines for the entire population (6 mo of age or older).
Introduction of this program was associated with greater overall
increases in influenza vaccination rates, particularly in children
and working-age adults, and greater reductions in influenza-
associated mortality and health care use in Ontario compared to
other provinces that maintained targeted programs [13,14].
The cost-effectiveness of universal vaccination has not been
evaluated, despite the investment of substantial financial resources.
The objective of this study was to conduct an economic appraisal
of Ontario’s UIIP.
Methods
An economic evaluation was performed to estimate health
outcomes and costs related to universal vaccination compared to
the hypothetical continuation of a targeted program for the entire
population of Ontario (12.16 million).
Data
All the input data are age specific (Tables S1 and S2) and used
as such in the calculations. The seven age groups are 4 y and
under, 5–19 y, 20–49 y, 50–64 y, 65–74 y, 75–84 y, and 85 y and
older. Most results are aggregated and reported for the total
program; supplementary information is available by age group
(Table S3).
Effectiveness of UIIP
This economic evaluation was informed by an earlier
epidemiological study that compared outcomes in Ontario before
and after universal immunization, using other provinces as
controls [13]. Introduction of Ontario’s UIIP was associated with
greater overall increases in influenza vaccination rates in Ontario
(from 18% in 1996 to 42% in 2005) compared to other provinces
(from 13% to 28%). Therefore, there was a 9-percentage-point
incremental increase in Ontario, and the relative increases were
most evident among those under 65 y. A different pattern was
observed among the elderly; for those aged 75 y or older, there
were greater relative increases among other provinces compared
to Ontario, although Ontario still maintained higher rates at all
times.
The impact of Ontario’s UIIP on influenza-associated mortality,
hospitalizations, and visits to emergency departments (EDs) and
doctors’ offices was estimated using data from 1997 to 2004 (3 y
before and 4 y after UIIP implementation). To estimate influenza-
associated outcomes, we used multivariate regression models to
predict events with influenza viral activity in the model, and we
subsequently removed the influenza terms (i.e., viral surveillance
data) from the model to generate a baseline function that
represented the hypothetical absence of influenza. To calculate
influenza-associated events, we subtracted the expected baseline
events from observed events during periods of influenza activity.
The models controlled for age, sex, province, influenza surveil-
lance data, and temporal trends. Influenza-associated event rates
in the overall population decreased 40%–60% more in Ontario
than in other provinces for all study outcomes. The relative
reductions were particularly prominent among age groups
younger than 65, consistent with the changes in vaccine uptake.
However, despite greater increases in vaccination rates among the
elderly in other provinces compared to Ontario, the reductions in
influenza-associated events among the elderly were either less
pronounced or the same in Ontario compared to other provinces.
The robustness of these findings was confirmed by numerous
sensitivity analyses [13]. For a more detailed description of the
regression model and results, see Text S1 and Table S6.
Side effects due to influenza vaccine were not included as they
are usually mild. While there is a small risk of hospitalization
because of Guillain-Barre ´ syndrome (GBS), a population-based
study found no statistically significant increase in hospital
admissions because of GBS after introduction of UIIP [15].
Resource Use: Physician Services and Hospitalizations
For the economic evaluation, the mean number of events per
season post-UIIP implementation as observed in Ontario was
compared with the expected number of events under hypothetical
continuation of TIIP (Table 1; more detailed information can be
found in Tables S1 and S2). To calculate the expected number of
events under hypothetical continuation of TIIP for Ontario, the
relative change of mean number of events pre-2000 (1997/1998 to
1999/2000) to post-2000 (2000/2001 to 2003/2004) observed in
other Canadian provinces was applied to the pre-UIIP event rates
in Ontario. This assumes that in Ontario vaccination coverage
rates would have increased and influenza-related events decreased
by the same relative magnitude as in other provinces after 2000.
All data were obtained for seven influenza seasons covering the
years from 1997 to 2004 [13]. Physician services data were
extracted from provincial datasets for Ontario (Ontario Health
Insurance Plan, OHIP) and three other Canadian provinces
(Quebec’s Physician Claims Dataset, Alberta’s Health Care
Insurance Plan Dataset, and Manitoba’s Medical Claims Dataset).
Hospitalization data were obtained from Statistics Canada’s
Hospital Morbidity Database, a national hospital discharge
dataset. Influenza-related events were identified using ICD 9/10
(International Statistical Classification of Diseases and Related
Health Problems) service codes associated with pneumonia or
influenza. These are complete datasets, covering all residents of
the respective provinces.
Influenza-associated events decreased more in Ontario than
other provinces: 75% versus 56% for hospitalizations, 69% versus
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[13].
Quality-Adjusted Life Years (QALYs) Lost from Influenza
The administrative data used to estimate resource use do not
yield a count of influenza cases. The number of cases of influenza
requiring health care was estimated using the number of office visits
and ED visits and excluding repeat visits by the same patient for the
same diagnosis within a 21-d window following an initial visit.
According to this approximation, 90% of all influenza-associated
office visits, 85% of all influenza-associated ED visits, and all
influenza-associated hospitalizations were deemed to be discrete
new cases of influenza. The remainder of visits were considered to
be repeat visits. Multiple visits across settings by the same patient
were not removed since the number of those was expected to be
small (for example, only 0.07% of all health care contacts were
hospitalizations, some of which may have had an office and/or ED
visit before being hospitalized). It was assumed that patients who die
due to influenza had at least one health care contact before death.
Therefore, these were also not separately counted as cases as they
were presumed to have been accounted for.
Quality weights as reported by Turner [16] were used to
estimate QALYs lost per case of influenza due to morbidity. In this
recent assessment by the National Institute for Health and Clinical
Excellence (NICE) of antiviral treatment of influenza, utilities for
influenza were estimated from patient health state valuations
reported daily for 21 d in oseltamivir clinical trials. Utilities were
generated by recalibrating the Likert scores as obtained in the
clinical trials to mean visual analogue scale scores, which were
then transformed to time trade-off scores. Quality of life data were
available for ‘‘otherwise healthy adults,’’ ‘‘adults with co-
morbidities,’’ and the ‘‘elderly.’’ In the absence of utility data for
children, it was assumed that children have similar utility weights
as ‘‘otherwise healthy adults’’ as both groups are similar in other
health outcome measures, such as time to return to normal activity
[17]. The utility weight for adults with co-morbidities as obtained
in the clinical trials was applied to the 18.8% of the Ontario
population aged 12 to 64 y deemed high risk because of chronic
conditions [18]. Patients in the trials were recruited from Europe
and North America. We assume that the clinical trial population is
sufficiently similar to the Ontario population (high income
Western countries with similar life expectancy and population
health status) so that we can apply the utility estimates to the
population under consideration here. The QALY gain per
influenza case prevented (Table 2) was calculated by multiplying
the duration of the symptomatic period by the utility decrement
associated with influenza-related illness.
To calculate QALYs lost due to premature death (Table 2), we
estimated influenza-associated deaths using mortality data from
Statistics Canada’s Mortality Database [13]. We considered deaths
due to all respiratory and circulatory conditions for seven influenza
seasons covering the years from 1997 to 2004. After UIIP
introduction, influenza-associated mortality decreased 77% in
Ontario compared to 46% in other provinces [13].
The average life expectancy was estimated by age [19] and
adjusted for quality of life, using utility scores from a community-
dwelling population, ranging from 0.88 to 0.94 depending on age
[20].
Quality-adjusted life expectancy was discounted at 3% per year
in the base case analysis [21].
Unit Costs: UIIP Program, Physician Services, and
Hospitalizations
All costs were obtained from Ontario sources and are expressed
in 2006 Canadian dollars. Cost data are summarized in Table 2.
The total program cost for the universal program was $40
million per year (approximately $3.96 per dose and $7.55 in total
per dose distributed) for each year since introducing the program
(Nancy Peroff-Johnston, Ministry of Health and Long-Term Care
[MOHLTC], personal communication, May 11, 2007). This
included the cost of the vaccine, health care provider reimburse-
ment for vaccination, communications strategies, and direct
operating expenditures for the MOHLTC including staffing.
Approximately 50% of the total budget was spent on the vaccine
and the remaining 50% on all other cost items. To calculate the
expected targeted program (TIIP) cost if universal immunization
(UIIP) had not been implemented, the relative change in vaccine
coverage (pre-2000 versus post-2000) observed in other provinces
was applied to Ontario’s pre-2000 vaccine coverage rate. Vaccine
coverage rates for the population 12 y or older more than doubled
(18% to 42%) in Ontario and other provinces (13% to 28%)
between 1996/1997 and 2005. The Ontario pre-2000 TIIP
program cost (Nancy Peroff-Johnston, MOHLTC, personal
communication, May 11, 2007) per person vaccinated was used,
inflated to 2006, and applied to the population who would have
been covered under a targeted program [22]. This assumes that
the average cost per person (including vaccine, vaccine delivery,
and other cost to the Ministry) remains the same but is applied to a
larger number of persons receiving influenza immunization. For
an expected TIIP coverage rate of 40%, the total program cost for
targeted immunization was expected to be $20 million if TIIP had
been continued.
Unit costs for physician services (office visits, ED visits, and in-
hospital services) were obtained from the OHIP dataset. A location
Table 1. Mean annual influenza-related event rates and relative rates comparing post-UIIP to pre-UIIP event rates.
Event
Number of Events per 100,000
Population in Ontario, Mean (95% CI) Post- vs. Pre-2000 Relative Rate, Mean (95% CI)
Pre-UIIP Post-UIIP Ontario
Other Provinces
Combined
Office visits 813.58 (807.90; 819.20) 173.00 (169.90; 176.10) 0.21 (0.21; 0.22) 0.52 (0.51; 0.53)
ED visits 139.57 (137.50; 141.70) 43.57 (42.20; 44.90) 0.31 (0.30; 0.32) 0.69 (0.67; 0.70)
Hospitalizations 33.38 (32.20; 34.60) 8.49 (7.70; 9.30) 0.25 (0.23; 0.28) 0.44 (0.42; 0.46)
Deaths 12.00 (11.05; 12.96) 2.79 (2.15; 3.42) 0.23 (0.18; 0.30) 0.33 (0.28; 0.39)
Source: Kwong [13].
CI, confidence interval; ED, emergency department; UIIP, universal influenza immunization program.
doi:10.1371/journal.pmed.1000256.t001
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the physician office, ED, or hospital.
Costs reflect the fee paid by condition type (pneumonia and
influenza). Mean fees paid ($35 per office visit, $54 per ED visit)
were used in the base case analysis; 95% CI defined the lower and
upper limit for deterministic sensitivity analysis. For probabilistic
analysis the primary data were sampled. An additional $166 per
ED visit was added for non-physician costs to calculate total cost
per ED visit [23].
Hospitalization costs were costed using the resource intensity
weight (RIW) approach [24,25]. The RIW is the ratio of the cost of
a case in a Case Mix Group (CMG) to the average cost of all cases.
The mean RIWs for pneumonia- or influenza-related hospitaliza-
tions were extracted from the acute care Discharge Abstract
Database (DAD). The provincial cost per weighted case of $4,732
was applied to the mean RIW of influenza-associated hospitaliza-
tions of 1.33 [23]. Mean physician charges for hospital inpatient
services for pneumonia or influenza (obtained from the OHIP
Table 2. Key data used in the economic evaluation.
Parameter
Base Case
Analysis, Mean Deterministic Sensitivity Analysis
Lower Confidence
Limit (Worst Case)
Upper Confidence
Limit (Best Case)
Per Influenza Case Prevented
0–4 y 0.0146 0.0065 0.0146
5–19 y 0.0146 0.0065 0.0146
20–49 y 0.0174 0.0097 0.0245
50–64 y 0.0174 0.0044 0.0245
65–74 y 0.0293 0.0233 0.0349
75–84 y 0.0293 0.0233 0.0349
85+ y 0.0293 0.0233 0.0349
Per Death Prevented
Undiscounted
0–49 y 62 N/A N/A
50–64 y 21 N/A N/A
65–74 y 11 N/A N/A
75–84 y 4 N/A N/A
85+ y1 N / A N / A
Discounted 3%
0–49 y 27 N/A N/A
50–64 y 14 N/A N/A
65–74 y 8 N/A N/A
75–84 y 4 N/A N/A
85+ y1 N / A N / A
Discounted 5%
0–49 y 18 N/A N/A
50–64 y 12 N/A N/A
65–74 y 7 N/A N/A
75–84 y 4 N/A N/A
85+ y1 N / A N / A
Unit Cost
Office visit $35 $18 $60
ED visit $220 $183 $371
Hospitalization $6,418 $2,075 $21,548
TIIP $19,946,556 $19,333,519 $20,944,646
UIIP $40,000,000 $40,000,000 $40,000,000
Source: quality of life with influenza: Turner [16]; life expectancy: Statistics Canada [19]; quality of life adjustment by age in the absence of influenza: Mittmann [20];
office visits, ED visits, hospitalizations: Ontario Health Insurance Plan (OHIP) dataset; TIIP: calculated based on influenza immunization program cost before
implementation of UIIP, vaccine coverage rates in Ontario pre-UIIP, and relative increase of influenza immunization coverage in other provinces [13,56] (Nancy Peroff-
Johnston, MOHLTC, personal communication, May 11, 2007); UIIP: Ministry of Health and Long-Term Care [56] (Nancy Peroff-Johnston, MOHLTC, personal
communication, May 11, 2007).
ED, emergency department; TIIP, targeted influenza immunization program; UIIP, universal influenza immunization program.
doi:10.1371/journal.pmed.1000256.t002
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1.65 claims for physician services per hospitalization at a cost of
$66.41 each. The average length of stay for pneumonia and
influenza is 6 d [26]. The total mean cost of a pneumonia- and
influenza-related episode of hospitalization was therefore $6,418.
Analyses
Cost-effectiveness. Cost-effectiveness of UIIP versus TIIP
was measured by the incremental cost-utility ratio (ICUR), defined
as the additional cost per QALY gained. The health benefits of
universal immunization were estimated as number of influenza
cases, health services utilization (physician visits, ED visits,
hospitalizations), and deaths prevented in a typical influenza
season. A time horizon of a lifetime was adopted to calculate
QALYs lost attributable to influenza-related death. Time
preference was incorporated by discounting QALYs lost at 3%
annually in the base case analysis [21]. Costs are not discounted
because all costs occur within 1 y. The analysis was performed from
the perspective of the health care payer, the Ontario MOHLTC.
Sensitivity analysis. The impact of data uncertainty was
explored with one-way and probabilistic sensitivity analyses. One-
way sensitivity analyses were performed for numbers of events,
number of cases, event costs, immunization program cost, QALY
penalty associated with influenza, and discount rate (undiscounted
and 5%). Grouped sensitivity analysis was performed by
simultaneously adjusting the values of (1) events (all events and
deaths separate), (2) relative rate (RR) of events (office visits, ED
visits, hospitalizations, and deaths, each event separate), (3) costs of
events (office visits, ED visits, and hospitalizations, each event
separate), and (4) QALY gain due to morbidity (illness) averted.
This was achieved by the use of scaling parameters that link
variables within a group and allow the simultaneous adjustment of
their values over a defined range. The base case value was
therefore multiplied with scaling parameter values ranging from 0
to 2. This range covers the 95% CI of all parameters except for
deaths observed post-UIIP in persons under 65 y of age. The
range for post-UIIP deaths is 24 to 6 for ,65 y old. This age
group (,65 y) accounts for approximately 2% of all deaths (7 out
of 309 deaths per season). We therefore assumed the range from 0
to 2 for scaling parameters to be acceptable for varying post-UIIP
deaths for all age groups combined (not individually). Two
extreme (best and worst) case scenarios were also performed
(Tables 1 and 2; more detailed information can be found in Tables
S1 and S2) biasing the analysis for and against UIIP. The 95% CIs
were used as extreme values for pre- and post-UIIP number of
events (cases, physician services, ED visits, hospitalizations,
deaths), RRs of events (to calculate number of events if TIIP
would have been continued), unit costs, and QALY loss
attributable to influenza morbidity.
For probabilistic analysis, distributions were assigned to key
variables in the model (Tables S1 and S2). Distributions for events
(office visits, ED visits, hospitalizations, and deaths), RRs, and unit
cost for events were drawn from the original data. For unit costs
for physician services, the actual administrative data were sampled
using $10.00 increments, with the last bin being $220 per visit and
greater (fees paid: $0t o,$10, $10 to ,$20, $20 to ,$30, … ,
$210 to ,$220, $220 and greater). The midpoint for the top and
bottom categories was adjusted by the minimum and maximum
fee charged. The midpoint for the bottom category was $5.50 for
office visits, $9.00 for ED visits, and $6.50 for inpatient services.
The midpoint for the top category was $225 for office visits and
inpatient services and $222 for ED visits. The midpoint of each bin
was used for calculation. For hospitalization cost, the RIW 95%
CI defined the lower and upper limit for deterministic sensitivity
analysis. For probabilistic analysis, the primary data were sampled.
Distributions for utility weights were based on confidence intervals
in published reports [16]. The probability of Ontario’s UIIP being
cost-effective for a range of willingness to pay thresholds ($0t o
$100,000 per QALY gained) was calculated by sampling from
these distributions running 1,000 trials. To ensure internal
consistency, the same random number was used to sample from
distributions for the different age brackets within the same group
of variables: pre-UIIP events, post-UIIP events, RR, and QALY
gain due to morbidity averted.
An additional analysis, using the diagnostic codes for all
respiratory conditions to extract health care utilization data, is
presented in the Text S2. This analysis was performed because
many influenza-related health care interactions are coded under
different diagnostic codes (e.g., common cold, asthma, COPD,
otitis media, etc.), therefore underestimating the health care
resource use due to influenza if using the diagnostic codes for
pneumonia and influenza only (as in all other analyses).
Results
Base Case
In Ontario, 22,457 cases of influenza were observed on average
per season after the introduction of the universal immunization
program. If TIIP had been continued, the expected average
number of cases per season was estimated to be 56,998. UIIP
therefore prevented 34,541 influenza cases (61% of all cases each
season).
Ontario’s UIIP also prevented 111 deaths, a 28% reduction in
mortality. This resulted in a projected 1,134 QALYs gained in
total or 0.09 quality-adjusted life days per person vaccinated.
Approximately half of all health gains (QALYs) were associated
with a reduction of influenza mortality; the other half was
associated with reduction in influenza-related morbidity.
The program costs of UIIP are high, approximately double that
of a targeted program ($40 million versus $20 million). However,
UIIP was estimated to prevent 786 influenza-related hospitaliza-
tions, 7,745 influenza-related ED visits, and 30,306 office visits per
season. Preventing influenza cases effectively reduced influenza-
related health care costs by 52%, saving the health care system
approximately $7.8 million per season, so that the net cost of the
UIIP program is $12.2 million, or $2.60 per person vaccinated.
The cost per QALY gained is $10,797/QALY (discount rate
3%). All base case results are presented in Table 3 and in more
detail in Table S3.
Sensitivity Analysis
Deterministic one-way sensitivity analysis (Figure 1, Table S4)
revealed that results are highly sensitive to the RR of deaths if
TIIP had been continued, the pre-UIIP and post-UIIP number of
deaths, and moderately sensitive to UIIP and TIIP immunization
program cost. However, the ICER remains below $50,000 per
QALY under the following conservative individual conditions: (1)
UIIP costs are twice the current program cost, (2) TIIP costs are
zero, (3) the RR of death is not smaller than 45% of the base case
value, (4) the pre-UIIP number of deaths is not smaller than 45%
of the base case value, or (5) the post-UIIP number of deaths is not
greater than 190% of the base case value.
It is highly unlikely that these thresholds for key parameters are
exceeded. Program costs were obtained from the Ontario Ministry
of Health and thus reflect the true costs to the Ministry. A RR of
death or a pre-UIIP number of deaths smaller than 45% of the
base case value is far outside the 95% CI for these values. The
95% CIs range from 92% to 108% of the base case value for pre-
Economics of Influenza Immunization
PLoS Medicine | www.plosmedicine.org 5 April 2010 | Volume 7 | Issue 4 | e1000256UIIP deaths (all ages) and from 85% to 118% of base case value
for RR of death (all ages). Similarly a post-UIIP number of deaths
greater than 190% of the base case value is outside the 95% CI
range for this variable (2260% to 120% of the base case value).
An analysis of extremes was also performed by examining best-
and worst-case scenarios (Table S5). In the worst-case scenario (UIIP
does not provide much health benefit over TIIP, health service
resource unit costs are low), UIIP increases program costs by $20
million, saves only $1.8 million in health care service cost, and incurs
a QALY loss. UIIP becomes unattractive because it is not associated
with health gain, and also increased costs compared to TIIP.
In the best-case scenario (UIIP is highly effective, health service
resource unit costs are high), UIIP increases program costs by
$19.1 million, saves $40.4 million in health care services, and gains
5,619 QALYs (discount rate 3%). UIIP dominates TIIP in this
scenario; i.e., UIIP is less costly and more effective than TIIP.
Probabilistic sensitivity analysis (Table 4, Figure 2) shows that
the probability of UIIP being cost-effective at a willingness-to-pay
threshold of $50,000 per QALY is exceeding 90%. The mean
(95% CI) QALYs gained are 1,263 [2456; 3,082], and the mean
(95% CI) net cost is $12.10 million [2$0.01 million; $16.11
million]. Finally, results for the additional analysis, using the
diagnostic codes for all respiratory conditions to extract health
care utilization data, are presented in Table S7.
Discussion
Our analysis suggests that Ontario’s UIIP is economically
attractive. UIIP reduces the number of influenza cases and deaths
and reduces health services resource use. The additional costs of
UIIP are partly (39%) offset by savings in health care costs.
Compared to TIIP, UIIP is cost-effective at an ICUR of $10,797
per QALY gained.
The main limitation in determining the impact of UIIP is the
ecologic study designofthe underlying effectivenessstudy.Causality
cannot be established with this type of study design. The effect size
may be exaggerated if there areprovince-specificepidemiological or
health service factors that have in more recent years reduced
influenza events in Ontario or increased it in other provinces.
Similarly, since the outcome measure is influenza-like illness rather
than confirmed influenza, it is possible that this could make
estimates of outcomes sensitive to changes in the epidemiology of
non-influenza respiratory illness. However, this design is appro-
priate for assessing the public health impact of a population-wide
intervention [13]. The results of Kwong’s analysis of observational
ecologic data in four provinces over 7 y are congruent with the
results of randomized controlled trial data in targeted groups.
Targeted immunization has been shown to be effective in
preventing laboratory-confirmed influenza infection in healthy
Table 3. Results—base case.
Outcome Measure TIIP UIIP Incremental (UIIP–TIIP) ICER ($/QALY)
Immunization program cost ($M) $19.95 $40.00 $20.05
Cost ($M)
Office visits $1.75 $0.68 2$1.07
ED visits $2.78 $1.07 2$1.70
Hospitalizations $10.87 $5.83 2$5.04
Total $15.40 $7.58 2$7.81
Net cost ($M) $12.24
Resource use
Office visits 49,638 19,332 230,306
ED visits 12.627 4,882 27,745
Hospitalizations 1,694 908 2786
Health outcome
Cases 56,931 22,390 234,541
Deaths 394 283 2111
QALYs (undiscounted)
Morbidity 2964 2412 552
Mortality 22,324 21,291 1,033
Total 23,289 21,703 1,585 $7,721
QALYs (discounted 3%)
Morbidity 2964 2412 552
Mortality 21,576 2994 581
Total 22,540 21,406 1,134 $10,797
QALYs (discounted 5%)
Morbidity 2964 2412 552
Mortality 21,330 2875 455
Total 22,294 21,287 1,007 $12,154
ED, emergency department; ICER, incremental cost-effectiveness ratio; $M, $ million; QALY, quality-adjusted life years; TIIP, targeted influenza immunization program;
UIIP, universal influenza immunization program.
doi:10.1371/journal.pmed.1000256.t003
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is a good match and virus circulation is high [28], and older adults
(65 y and older), especially in long-term care facilities [28]. The
weight of evidence seems to support the hypothesis that UIIP has
been responsible for the decrease in cases and deaths in Ontario, in
the absence of other obvious causal mechanisms. Stronger
randomised clinical trial evidence of the effectiveness of universal
vaccination in large populations is unlikely to be available in the
future. Finally, to test whether the disproportionate decrease in
influenza events from a 9% difference in coverage improvement
may be attributable to herd immunity, we analyzed a simple
Susceptible-Infected-Removed (SIR) compartmental model (for a
description of the model and results, see Figures S1 and S2, Tables
S7 and S8, and Text S3). This basic analysis suggests that the 40%–
60% decrease in influenza events is plausible.
Other study limitations relate to the definition of cases and
quality of life estimates used. Cases were defined based on health
care resource use for pneumonia and influenza and therefore
represent influenza-like illness cases. Symptomatic cases not
requiring health care contacts are not included, potentially
underestimating the benefit of the program. Utility weights to
estimate QALYs were obtained from an analysis of clinical trial
data from influenza patients in Europe and North America [16].
While these data are not Canada-specific, the populations are
similar. Furthermore, sensitivity analysis was performed and
reported for utility weights used in the analysis.
Figure 1. Tornado diagram comparing the relative importance of variables. The grey vertical line corresponds to all the uncertain
parameters being at their respective base values. The width of the bars indicates the uncertainty associated with each parameter (ranging from lower
to upper limit). The red segments of the bars correspond to result values increasing the base case ICER, and the blue segments of the bars correspond
to result values decreasing the base case ICER. ED, emergency department; QALY, quality-adjusted life year; RR, relative rate; TIIP, targeted influenza
immunization program; UIIP, universal influenza immunization program.
doi:10.1371/journal.pmed.1000256.g001
Table 4. Results—probabilistic sensitivity analysis.
Analysis Net Cost ($M) Net QALYs
a
Deterministic $12.24 1,134
Probabilistic
Mean $12.10 1,263
Median $13.46 1,190
2.5th percentile 2$0.01 2456
97.5th percentile $16.11 3,082
aDiscounted at an annual rate of 3%.
$M, $ million; QALY, quality-adjusted life years.
doi:10.1371/journal.pmed.1000256.t004
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based on administrative health care resource use and cost data
covering all residents of Ontario. Data were extracted and
analyzed in detail to estimate influenza-associated events and
costs as accurately as possible to assess the impact of this
intervention on the population of interest rather than estimating
parameter values from other, smaller subpopulations that may not
be representative. Finally, extensive sensitivity analyses demon-
strated the program to be effective and cost-effective under very
conservative assumptions.
The cost-effectiveness of influenza immunization programs
has been demonstrated by numerous economic evaluations of
TIIPs, many of which are directly based on clinical trial data.
TIIPs have been shown to be cost-effective in children 6 mo and
older [29–36], adults 50 y and older [37–41], working adults
[42–44], working adult cancer patients [45], pregnant women
[46], health care workers [47,48], high-risk individuals [49],
and older adults (65 y and older) [39,50–55] from a health care
payer perspective. Most economic evaluations found TIIPs
to be not only cost-effective but cost-saving from a societal
perspective.
Policy makers in many jurisdictions considering the implemen-
tation of universal immunization have expressed interest in an
economic evaluation of Ontario’s program. The program appears
to offer some health benefits, but the relationship between cost and
health benefits of universal immunization had not been evaluated.
Our study provides evidence that a universal program is
economically attractive in jurisdictions with influenza epidemiol-
ogy and health care costs that are broadly similar to that of
Ontario.
A UIIP may be an appealing intervention in high-income
jurisdictions with comparable demographic characteristics (age
distribution, risk profile, density) where influenza transmission can
be expected to be reasonably similar to the population analyzed. A
health care system similar to Ontario’s (i.e., health care systems
with one major payer), where the costs of the immunization
program and the costs of treating influenza cases are both in the
payer’s budget, will enable the universal program costs to be partly
offset by savings in health care cost.
Conclusion
This analysis indicates that compared to a TIIP, Ontario’s UIIP
reduces influenza illness attack rates, morbidity, and mortality at
reasonable cost to the health care payer.
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Background. Annual outbreaks (epidemics) of influenza—a
viral disease of the nose, throat, and airways—make millions
of people ill and kill about 500,000 individuals every year. In
doing so, they impose a considerable economic burden on
society in terms of health care costs and lost productivity.
Influenza epidemics occur because small but frequent
changes in the viral proteins to which the immune system
responds mean that an immune response produced one year
by exposure to an influenza virus provides only partial
protection against influenza the next year. Annual
immunization with a vaccine that contains killed influenza
viruses of the major circulating strains can boost this natural
immunity and greatly reduce a person’s chances of catching
influenza. Consequently, many countries run seasonal
influenza vaccine programs. These programs usually target
people at high risk of complications from influenza and
individuals likely to come into close contact with them, and
people who provide essential community services. So, for
example, in most Canadian provinces, targeted influenza
immunization programs (TIIPs) offer free influenza
vaccinations to people aged 65 years or older, to people
with chronic medical conditions, and to health care workers.
Why Was This Study Done? Some experts argue,
however, that universal vaccination might provide
populations with better protection from influenza. In 2000,
the province of Ontario in Canada decided, therefore, to
introduce a universal influenza immunization program (UIIP)
to provide free influenza vaccination to everyone older than
6 months, the first large program of this kind in the world. A
study published in 2008 showed that, following the
introduction of the UIIP, vaccination rates in Ontario
increased more than in other Canadian provinces. In
addition, deaths from influenza and influenza-related use
of health care facilities decreased more in Ontario than in
provinces that continued to offer a TIIP. But is universal
influenza vaccination good value for money? In this study,
the researchers evaluate the cost-effectiveness of the Ontario
UIIP by comparing the health outcomes and costs associated
with its introduction with the health outcomes and costs
associated with a hypothetical continuation of targeted
influenza immunization.
What Did the Researchers Do and Find? The researchers
used data on TIIP and UIIP vaccine uptake, physician visits,
emergency department visits, hospitalizations for influenza,
and deaths from influenza between 1997 and 2004 in
Ontario and in nine Canadian states offering TIIPs, and
Ontario cost data, in their ‘‘cost-utility’’ analysis. This type of
analysis estimates the additional cost required to generate a
year of perfect health (a quality-adjusted life-year or QALY)
through the introduction of an intervention. QALYs are
calculated by multiplying the time spent in a certain health
state by a measure of the quality of that health state. The
researchers report that the cost of Ontario’s UIIP was about
twice as much as the cost of a TIIP for the province. However,
the introduction of the UIIP reduced the number of influenza
cases by nearly two-thirds and reduced deaths from
influenza by more than a quarter compared with what
would have been expected had the province continued to
offer a TIIP, an overall saving of 1,134 QALYs. Furthermore,
the reduction in influenza cases halved influenza-related
health care costs, mainly because of reductions in
hospitalization. Overall, this means that the additional cost
to Ontario of saving one QALY through the introduction of
the UIIP was Can$10,797, an ‘‘incremental cost-effectiveness
ratio’’ of $10,797 per QALY gained.
What Do These Findings Mean? In Canada, an
intervention is considered cost-effective from the point of
view of a health care purchaser if it costs less than Canadian
$50,000 to gain one QALY. These findings indicate, therefore,
that for Ontario the introduction of the UIIP is economically
attractive. Indeed, the researchers calculate that even if the
costs of the UIIP were to double, the additional cost of
saving one QALY by introducing universal immunization
would remain below $50,000. Other ‘‘sensitivity’’ analyses
undertaken by the researchers also indicate that universal
immunization is likely to be effective and cost-effective in
Ontario if other key assumptions and/or data included in the
calculations are varied within reasonable limits. Given these
findings, the researchers suggest that a UIIP might be an
appealing intervention in other Canadian provinces and in
other high-income countries where influenza transmission
and health-care costs are broadly similar to those in Ontario.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1000256.
N A PLoS Medicine Research Article by Kwong and colleagues
describes how the introduction of universal influenza
immunization in Ontario altered influenza-related health
care use and deaths in the province
N Wikipedia pages are available on QALYs and on cost-utility
analysis (note that Wikipedia is a free online encyclopedia
that anyone can edit; available in several languages)
N Bandolier, an independent online journal about evidence-
based health-care, provides information about QALYs and
their use in cost-utility analysis
N The UK National Institute for Health and Clinical Excellence
has a webpage on Measuring effectiveness and cost-
effectiveness: the QALY
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